• Home
  • NEW DAY MEDICINE
  • 1 (29) 2020 г.
  • 64 -1 (29/2) 2020 — Latipov I.I., Maxmudov F.A., — ASSESSMENT OF THE CLINICAL EFFICIENCY OF THE UTILIZATION OF PLATELET RICH PLASMA IN THE THERAPY OF VITILIGO

64 -1 (29/2) 2020 — Latipov I.I., Maxmudov F.A., — ASSESSMENT OF THE CLINICAL EFFICIENCY OF THE UTILIZATION OF PLATELET RICH PLASMA IN THE THERAPY OF VITILIGO

ASSESSMENT OF THE CLINICAL EFFICIENCY OF THE UTILIZATION OF PLATELET RICH PLASMA IN THE THERAPY OF VITILIGO

Latipov I.I., Bukhara State Medical Institute.

Maxmudov F.A., Bukhara State Medical Institute.

Ozodov J.H., Bukhara State Medical Institute.

Baxshilloyeva R.E., Bukhara State Medical Institute.

Resume,

Aim: to study the clinical efficiency and safety of platelet rich plasma (PRP) injection in the cure of limited vitiligo.

Patients and Methods: 48 patients with vitiligo aged from 19 to 59 years (35 women and 13 men) with the duration of the disease from 7 months to 12 years were examined. Patients were divided into 2 groups: group 1 (comparison group) – 25 vitiligo patients, treated with photodynamic therapy; group 2 (main group) – 23 patients, who received PRP injections as part of complex therapy. To compare laboratory studies, data from 28 healthy donors (control group) were used.

Results: the study showed a similar effectiveness of the use of phototherapy and PRP in the treatment of restricted forms of vitiligo in both methods. It was found that the use of PRP allows to obtain clinical remission (full, severe and moderate effect) in 87.5% of cases. Analysis of levels of proinflammatory cytokines showed that the use of this method in the treatment of vitiligo is pathogenetically justified, which was confirmed by a significant decrease in the concentrations of interleukins 1, 8, 10 and tumor necrosis factor a in patients with both groups of blood relative to baseline values. The assessment of the dynamics of vascular endothelial growth factor (VEGF) showed that the level of the indicator was significantly higher than the control level before the start of treatment, then after a treatment in both groups of vitiligo patients there was a significant decrease in the VEGF concentration as compared to the baseline level. It was found that the use of PRP resulted in a significant increase in the level of melanin in more 2 times in the foci of the disease; similar was the increase in this parameter in the group of patients who received phototherapy. The absence of undesirable phenomena in both groups of patients during the observation period was noted. It was found that the use of PRP in the treatment of vitiligo is safe, not accompanied by side effects, allergic and toxic reactions.

Conclusions: the method of utilization platelet rich plasma in the treatment of vitiligo is clinically effective and safe, as its use makes it possible to obtain clinical remission in 87.5% of patients.

Key words: vitiligo, depigmentation, melanin, platelet-rich plasma, immune system, photodynamic therapy, cytokines, vascular endothelial growth factor.

First page

235

Last page

238

For citation: Latipov I.I., Maxmudov F.A., Ozodov J.H., Baxshilloyeva R.E., Assessment of the clinical efficiency of the utilization of platelet rich plasma in the therapy of vitiligo//New Day in Medicine 1(29)2020 235-238 https://cutt.ly/QvCd6xH

List of References

  1. Haider R.M., Chappell J.L. Vitiligo update. Semin Cutan Med Surg 2016; 28(2): 86-92.
  2. Bolognia J.L., Jorizzo J.L., Rapini R.P. Dermatology. 2nd Revised edition: Elsevier Health Sciences 2017; Chapter 65.
  3. Taieb A., Picardo M., VETF Members. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 2007; 20(l):27-35.
  4. National Institute of Arthritis, Musculoskeletal, and Skin Diseases, what is vitiligo? Fast facts: an easy-to-read series of publications for the public additional”. Retrieved 2007.
  5. Kovacs SO. Vitiligo. J Am Acad Dermatol 1998; 38(l): 647-66.
  6. Le Poole I.C., Das P.K., Van Den Wijngaard R.M., Bos J.D., Westerhof W. Review of the etiopathomechanism of vitiligo: a convergence theory. Exp Dermatol 1993; 2(4): 145-53.
  7. Oakley A.M. Rapid depigmentation after depigmentation therapy: vitiligo treated with mono benzyl ether of hydroquinone. Austral as J Dermatol 1996; 37(2): 96-98.
  8. Passeron T., Ortonne J.P. Physiopathology and genetics of vitiligo. J Autoimmune 2015; 25(S):63-68.
  9. Hitton M.E., Ashcroft D.M., Gonzalez U. Therapeutic interventions for vitiligo. // J Am Acad Dermatol 2008; 59(4):713-17.
  10. Anon. Vitiligo -treatment. Patient UK. NHS. Retrieved 2013; 06­03.
  11. Scherschun L., Kim J.J., Lim H.W. Narrow-band ultraviolet В is a useful and well-tolerated treatment for vitiligo. J Am Acad Dermatol 2001; 44(6):999-1003.
  12. Philip D., Aurel I., Anne D., Kathleen H. Treatment of vitiligo with broadband ultraviolet В and vitamins. Int J Dermatol 2016; 45(l):63-5.
  13. Nistico S., Chiricozzi A., Saraceno R., Schipani C., Chimenti S.. Vitiligo treatment with monochromatic excimer light and tacrolimus: results of an open randomized controlled study. Photomed Laser Surg 2012; 30(l):.26-30.
  14. Juhlin L., Olsson M.J. Improvement of vitiligo after oral treatment with vitamin В12 and folic acid and the importance of sun exposure. Acta Derm Venereol 1997; 77(6):460-62.

file

download